Psychedelic Sector Week in Review: January 26 – February 1, 2026

Catching you up on the week of January 26 – February 1, 2026: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.

Optimi Health Corp. (OPTI): Optimi Health completes first 2026 production run of MDMA and psilocybin capsules

Optimi Health, a Health Canada-licensed GMP manufacturer, completed its first 2026 production cycle of 1,000 MDMA capsules (60 mg) and 1,000 naturally derived psilocybin capsules (5 mg) destined for Australia under that country's Authorised Prescriber Scheme. The batch reinforces Optimi's role as a commercial supplier feeding Australia's regulated psychedelic-assisted therapy market, including insurer-backed programs. The run demonstrates ongoing revenue-generating drug supply while many peers remain pre-commercial.

Source: biospace.com

That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.